Cargando…
The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers
Gynecologic cancers account for approximately 11% of the newly diagnosed cancers in women in the United States and for 18% globally. The presence of tumor-infiltrating lymphocytes (TILs) influences the clinical outcome of cancer patients and immune checkpoint inhibitors (ICIs), including anti progra...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404077/ https://www.ncbi.nlm.nih.gov/pubmed/32708748 http://dx.doi.org/10.3390/ijms21145034 |
_version_ | 1783567072293289984 |
---|---|
author | Kooshkaki, Omid Derakhshani, Afshin Safarpour, Hossein Najafi, Souzan Vahedi, Parviz Brunetti, Oronzo Torabi, Mitra Lotfinejad, Parisa Paradiso, Angelo Virgilio Racanelli, Vito Silvestris, Nicola Baradaran, Behzad |
author_facet | Kooshkaki, Omid Derakhshani, Afshin Safarpour, Hossein Najafi, Souzan Vahedi, Parviz Brunetti, Oronzo Torabi, Mitra Lotfinejad, Parisa Paradiso, Angelo Virgilio Racanelli, Vito Silvestris, Nicola Baradaran, Behzad |
author_sort | Kooshkaki, Omid |
collection | PubMed |
description | Gynecologic cancers account for approximately 11% of the newly diagnosed cancers in women in the United States and for 18% globally. The presence of tumor-infiltrating lymphocytes (TILs) influences the clinical outcome of cancer patients and immune checkpoint inhibitors (ICIs), including anti programmed cell death protein-1 (anti-PD-1), anti-programmed death-ligand 1 (anti-PD-L1), and anticytotoxic T-lymphocyte antigen 4 (anti-CTLA-4), which have been approved for treating different types of malignancies. Antibodies targeting the PD-1/PD-L1 checkpoint have shown dynamic and durable tumor regressions, suggesting a rebalancing of the host–tumor interaction. There are several the US food and drug administration (FDA)-approved ICIs targeting PD-1, including pembrolizumab and nivolumab, as well as those targeting PD-L1, including avelumab, atezolizumab, and durvalumab for melanoma, renal cell cancer, colorectal cancer, head and neck cancer, cervix cancer, urothelial cancer, and lung cancer. Current pre-clinical and clinical studies assessing PD-1/PD-L1 inhibitors in several gynecologic cancers have reported significant antitumor activity. In this review, we investigate pre-clinical and clinical studies that describe the safety and efficacy of anti-PD-1/PD-L1 antibodies, with a particular focus on ongoing clinical trials, analyzing the oncological outcome and adverse effects of ICIs in gynecologic cancers. |
format | Online Article Text |
id | pubmed-7404077 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74040772020-08-11 The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers Kooshkaki, Omid Derakhshani, Afshin Safarpour, Hossein Najafi, Souzan Vahedi, Parviz Brunetti, Oronzo Torabi, Mitra Lotfinejad, Parisa Paradiso, Angelo Virgilio Racanelli, Vito Silvestris, Nicola Baradaran, Behzad Int J Mol Sci Review Gynecologic cancers account for approximately 11% of the newly diagnosed cancers in women in the United States and for 18% globally. The presence of tumor-infiltrating lymphocytes (TILs) influences the clinical outcome of cancer patients and immune checkpoint inhibitors (ICIs), including anti programmed cell death protein-1 (anti-PD-1), anti-programmed death-ligand 1 (anti-PD-L1), and anticytotoxic T-lymphocyte antigen 4 (anti-CTLA-4), which have been approved for treating different types of malignancies. Antibodies targeting the PD-1/PD-L1 checkpoint have shown dynamic and durable tumor regressions, suggesting a rebalancing of the host–tumor interaction. There are several the US food and drug administration (FDA)-approved ICIs targeting PD-1, including pembrolizumab and nivolumab, as well as those targeting PD-L1, including avelumab, atezolizumab, and durvalumab for melanoma, renal cell cancer, colorectal cancer, head and neck cancer, cervix cancer, urothelial cancer, and lung cancer. Current pre-clinical and clinical studies assessing PD-1/PD-L1 inhibitors in several gynecologic cancers have reported significant antitumor activity. In this review, we investigate pre-clinical and clinical studies that describe the safety and efficacy of anti-PD-1/PD-L1 antibodies, with a particular focus on ongoing clinical trials, analyzing the oncological outcome and adverse effects of ICIs in gynecologic cancers. MDPI 2020-07-16 /pmc/articles/PMC7404077/ /pubmed/32708748 http://dx.doi.org/10.3390/ijms21145034 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kooshkaki, Omid Derakhshani, Afshin Safarpour, Hossein Najafi, Souzan Vahedi, Parviz Brunetti, Oronzo Torabi, Mitra Lotfinejad, Parisa Paradiso, Angelo Virgilio Racanelli, Vito Silvestris, Nicola Baradaran, Behzad The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers |
title | The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers |
title_full | The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers |
title_fullStr | The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers |
title_full_unstemmed | The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers |
title_short | The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers |
title_sort | latest findings of pd-1/pd-l1 inhibitor application in gynecologic cancers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404077/ https://www.ncbi.nlm.nih.gov/pubmed/32708748 http://dx.doi.org/10.3390/ijms21145034 |
work_keys_str_mv | AT kooshkakiomid thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT derakhshaniafshin thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT safarpourhossein thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT najafisouzan thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT vahediparviz thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT brunettioronzo thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT torabimitra thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT lotfinejadparisa thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT paradisoangelovirgilio thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT racanellivito thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT silvestrisnicola thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT baradaranbehzad thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT kooshkakiomid latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT derakhshaniafshin latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT safarpourhossein latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT najafisouzan latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT vahediparviz latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT brunettioronzo latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT torabimitra latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT lotfinejadparisa latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT paradisoangelovirgilio latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT racanellivito latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT silvestrisnicola latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers AT baradaranbehzad latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers |